The Food and Drug Administration (FDA) is advising consumers not to purchase or use Diamond 3500, a product promoted and sold for sexual enhancement on various websites and in some retail stores.

The Food and Drug Administration (FDA) is advising consumers not to purchase or use Eros Power Zone 1900, a product promoted and sold for sexual enhancement on various websites and in some retail stores.

The Food and Drug Administration (FDA) is advising consumers not to purchase or use Triple MiracleZen Gold 1750 mg, a product promoted and sold for sexual enhancement on various websites and in some retail stores.

The Food and Drug Administration (FDA) is advising consumers not to purchase or use Xtra Zone 2400, a product promoted and sold for sexual enhancement on various websites and in some retail stores.

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

On November 9, 2012, Ranbaxy Inc. initiated a voluntary recall of 41 affected lots of atorvastatin calcium tablets (10 mg, 20 mg and 40 mg) which is a solid oral dosage form, to the retail level.

Important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins are being announced today by the U.S. Food and Drug Administration. These products, when used with diet and exercise, help to lower a person’s “bad” cholesterol (low-density lipoprotein cholesterol). The products include: Lipitor ( atorvastatin ), Lescol ( fluvastatin ), Mevacor ( lovastatin ), Altoprev ( lovastatin extended-release), Livalo ( pitavastatin ), Pravachol ( pravastatin ), Crestor ( rosuvastatin ), and Zocor ( simvastatin ). Combination products include: Advicor (...

The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta ( ticagrelor ) to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS).

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy , particularly during the first 12 months of use.